Pipeline Programs

About Harmony Biosciences

Harmony Biosciences is a publicly traded, patient-centric biopharmaceutical company dedicated to advancing treatments for rare neurological disorders. The company has achieved commercial success with WAKIX® for narcolepsy and is actively expanding its pipeline into new indications and rare epilepsies. With a reiterated 2026 net revenue guidance of over $1 billion, Harmony is demonstrating strong financial performance and strategic growth in the neurology space.

About Harmony Biosciences

Harmony Biosciences is a publicly traded, patient-centric biopharmaceutical company dedicated to advancing treatments for rare neurological disorders. The company has achieved commercial success with WAKIX® for narcolepsy and is actively expanding its pipeline into new indications and rare epilepsies. With a reiterated 2026 net revenue guidance of over $1 billion, Harmony is demonstrating strong financial performance and strategic growth in the neurology space.

Therapeutic Areas